We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Marina Biotech Completes Enrollment of its First Cohort in the START-FAP Clinical Trial of CEQ508
Product News

Marina Biotech Completes Enrollment of its First Cohort in the START-FAP Clinical Trial of CEQ508

Marina Biotech Completes Enrollment of its First Cohort in the START-FAP Clinical Trial of CEQ508
Product News

Marina Biotech Completes Enrollment of its First Cohort in the START-FAP Clinical Trial of CEQ508


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Marina Biotech Completes Enrollment of its First Cohort in the START-FAP Clinical Trial of CEQ508"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Marina Biotech, Inc. has announced the completion of enrollment in the first cohort of its START-FAP (Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis), Phase 1b/2a clinical trial with CEQ508.

This cohort makes up the first group in the Dose Escalation Phase consisting of three patients who will receive the starting and lowest dose level of 1x10(8) colony forming units (cfu)/day.

The study drug is administered as an oral, daily drink for 28 days. Marina Biotech's Phase 1b/2a trial is an open-label, escalating-dose study of single daily doses of CEQ508 and will be conducted as a single center study in Boston, Massachusetts.

"I'm very pleased with the substantial progress we've made in patient enrollment and initiating first-in-man dosing in this cohort of FAP patients," stated Daniel C. Chung, MD, Principal Investigator of the START-FAP trial and gastroenterologist at Massachusetts General Hospital.

Chung continued, "We're into our second week of drug administration with our first patient and anticipate dosing the subsequent two patients in this group in the coming weeks. The current lack of acceptable pharmaceutical options for this serious disease represents a significant unmet medical need."

Further, Marina Biotech announced that the Australian Patent Office has issued a Notice of Allowance for patent application AU2005316458 with claims that broadly cover attenuated bacteria as a therapeutic platform for the delivery of short interfering RNA (siRNA) molecules that target disease-related genes (tkRNAi platform), including beta-catenin, whose dysregulation is implicated in the hyperproliferation and polyp formation characteristic of FAP, as well as being a key oncogene associated with the development of colorectal and other cancers.

This allowed patent is part of a global patent portfolio with broad genus claims to the tkRNAi platform, which was developed and filed by the Beth Israel Deaconess Medical Center (BIDMC). Marina Biotech has an exclusive license to the tkRNAi platform from BIDMC.

In addition, Marina Biotech owns U.S. and international patent applications that protect improvements to the tkRNAi platform for the generation of new drug candidates. In total, the global patent estate for the tkRNAi platform includes issued or allowed patents in Korea, Australia, and countries throughout Europe, and pending patent applications in the U.S., Canada and Japan.

Advertisement